Telaprevir-based regimen cures HCV patients in study

09/7/2010 | Bloomberg Businessweek

A drug cocktail that included Vertex Pharmaceuticals' telaprevir in a late-stage study cured about 65% of hepatitis C patients who had not responded to other therapies, compared with 17% of those given the standard combination of pegylated interferon and ribavirin. The best outcomes were seen in patients who previously had a relapse.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC